Method of diagnosing and/or monitoring therapy of atherosclerosis
AssigneeStc.Unm
InventorJeffrey P. Norenberg
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. The methods described herein are able to diagnose, treat and/or monitor the therapy of numerous diseases and conditions including atherosclerosis, atherothrombosis, cerebral vascular disease, cerebral ischemia, cerebral infarct and meningitis as well as pneumonitis, pericarditis, multiple sclerosis, lupus erythematosus and pancreatitis, among others.
Claims20
A method of diagnosing the existence of a ICAM-1/LFA-1 mediated disease or condition in tissue of a patient comprising administering to said patient an effective amount of at least one compound according to the chemical structure:
- Where Y is a chemical linker which links the nitrogen to a chelate group or tricarbonyl complex X, wherein X Incorporates or complexes with a radioisotope, or
- a pharmaceutically acceptable salt thereof;
- measuring the amount of said compound which binds to said tissue in said patient;
- and comparing the measurement obtained in said measuring step with a standard from uninfected tissue or infected tissue, wherein said measurement obtained from said patient is compared to said standard(s) and said comparison is determined to be indicative of the existence or the absence of a disease or condition in said tissue,
- wherein said disease state or condition is atheroma, atherothrombosis or a combination of atheroma and atherothrombosis.
A method of monitoring the treatment of a ICAM-1/LFA-1 mediated disease or condition in tissue of a patient comprising administering to said patient undergoing a course of treatment for said disease or condition an effective amount of at least one compound according to the chemical structure:
- Where Y is a chemical linker which links the nitrogen to a chelate group or tricarbonyl complex X, wherein X incorporates or complexes with a radioisotope, or
- a pharmaceutically acceptable salt thereof;
- measuring the amount of said compound which binds to said tissue in said patient at two different times or more during treatment;
- and comparing the measurements obtained in said measuring step at said different times with a standard from normal tissue and/or tissue impacted by said disease state and/or condition, wherein said measurements obtained from said patient are compared to said standard(s) and optionally, to each other, such that said comparison is indicative of the progress or absence of progress in the treatment of said disease or condition wherein said disease or condition is atheroma, atherothrombosis or a combination of atheroma and atherothrombosis.
A method of treating a ICAM-1/LFA-1 mediated disease or condition in tissue of a patient in heed wherein said disease is atherothrombosis comprising administering to said patient an effective amount of at least one compound according to the chemical structure:
- Where Y is a chemical linker which links the nitrogen to a chelate group or tricarbonyl complex X, wherein X incorporates or complexes with a radioisotope, or
- a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.